65350-86-9 Usage
General Description
The chemical compound "(2R-trans)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3-methoxy-2H-1-benzopyran-5,7-diol" is a flavonoid derivative with antioxidant properties. It is a trans-isomer of the flavonoid, which means that the two substituents on the second carbon atom are on opposite sides of the double bond. (2R-trans)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-3-methoxy-2H-1-benzopyran-5,7-diol contains a benzopyran ring with hydroxyl and methoxy groups attached, giving it potent antioxidant and anti-inflammatory properties. Flavonoids are known to have beneficial effects on human health, including reducing the risk of chronic diseases such as heart disease and cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 65350-86-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,3,5 and 0 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 65350-86:
(7*6)+(6*5)+(5*3)+(4*5)+(3*0)+(2*8)+(1*6)=129
129 % 10 = 9
So 65350-86-9 is a valid CAS Registry Number.
InChI:InChI=1/C16H16O6/c1-21-15-7-10-12(19)5-9(17)6-14(10)22-16(15)8-2-3-11(18)13(20)4-8/h2-6,15-20H,7H2,1H3/t15-,16+/m0/s1
65350-86-9Relevant articles and documents
FLAVONOID COMPOUNDS
-
, (2014/09/29)
The present invention relates to compounds, compositions, and methods for treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more epicatechin derivatives in an amount effective to stimulate mitochondrial function in cells. The compounds, compositions, and methods described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.
